Læknablaðið : fylgirit - 01.05.2002, Blaðsíða 2

A first line treatment for relapsing-remitting MS
ln one of the most extensive clinical trials to date with beta-interferon-1a (PRISMS1),
Rebif®44mcgx3 demonstrated superior efficacy in criteria of disease progression when
compared to the lower-dose of Rebif®, including delay of disability and reduction in
frequency and severity of relapses. These results suggest that the well-tolerated regimen
of Rebif®44mcgx3 is preferable to the lower-dose of Rebif®, and that therapy initiated
early provides benefit over therapy that is delayed.
For patients with relapsing-remitting MS, Rebif®44mcgx3 can help change the course of
the disease... to help maintain the course of normal life, for longer.
Rebif44,„x3.
Interferon beta-1a
Life Goes On...
-- serono
biotech & beyon>